Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Number of employees : 88 people.
Managers
NameAgeSinceTitle
Maria Fardis, Dr.502016President, Chief Executive Officer & Director
Iain D. Dukes, Dr.592016Chairman
Timothy E. Morris562017Secretary, Chief Financial & Accounting Officer
Friedrich Graf Finckenstein, Dr.-2019Chief Medical Officer
Merrill A. McPeak822016Independent Director
Ryan D. Maynard482015Independent Director
Wayne P. Rothbaum502016Independent Director
Michael Weiser, Dr.552018Independent Director
Athena Countouriotis, Dr.462019Independent Director
Richard Gaeto--Senior Vice President-Technical Operations
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 126,194,915 125,368,894 99.3% 0 0.0% 99.3%
Stock B 0 194 0 0.0% 0 0.0%
Stock C 0 3,581,119 0 0.0% 0 0.0%
Shareholders
NameEquities%
Perceptive Advisors LLC 11,014,702 8.73%
Avoro Capital Advisor LLC 10,601,039 8.40%
The Vanguard Group, Inc. 10,269,067 8.14%
Quogue Capital LLC 7,067,333 5.60%
Franklin Advisers, Inc. 6,530,176 5.17%
T. Rowe Price Associates, Inc. (Investment Management) 6,505,083 5.15%
Farallon Capital Management LLC 6,025,000 4.77%
OrbiMed Advisors LLC 5,548,326 4.40%
Great Point Partners LLC 5,260,803 4.17%
SSgA Funds Management, Inc. 4,758,219 3.77%
Company contact information
Iovance Biotherapeutics, Inc.
999 Skyway Road
Suite 150
San Carlos, CA 94070

Phone : +1.650.260.7120
Web : http://www.iovance.com
Sector Bio Diagnostics & Testing
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.195.37%3 299
GUARDANT HEALTH, INC.101.92%7 127
GENSCRIPT BIOTECH CORPORATION77.52%4 475
INVITAE CORPORATION55.15%1 656
VERACYTE, INC.126.63%1 392
MIRACA HOLDINGS INC.8.31%1 374
CAREDX, INC-13.48%923
SEEGENE INC--.--%609
INNATE PHARMA-26.90%475
EPIGENOMICS AG-19.55%67
LYSOGENE2.81%25